Combined Therapeutic Effects of Ganoderma lucidum-Derived Exosome-Like Nanovesicles and Celastrol in a Rat Model of Collagen-Induced Rheumatoid Arthritis
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Brieflands
Abstract
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation and progressive joint destruction, driven primarily by an imbalance between proinflammatory and anti-inflammatory cytokines. Objectives: This study investigated, for the first time, the therapeutic efficacy of Ganoderma lucidum-derived exosome-like nanovesicles (GLENVs), celastrol, and their combined immunomodulatory activity in rats with collagen-induced arthritis (CIA), a model of RA. Methods: GLENVs were purified and characterized using dynamic light scattering (DLS). Collagen-induced arthritis (CIA) was induced in Sprague-Dawley rats, and disease severity was evaluated using a standardized scoring system. After CIA had developed, rats were assigned to a vehicle control group receiving phosphate-buffered saline (PBS) plus 10% DMSO, a GLENV-treated group, a celastrol-treated group, or a combination treatment group. Enzyme-linked immunosorbent assay (ELISA) was used to measure serum levels of tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β, IL-6, IL-10, and transforming growth factor-beta (TGF-β). The expression of inflammatory mediators, including Janus kinase 1 (JAK1), signal transducer and activator of transcription 3 (STAT3), cyclooxygenase-2 (COX-2), matrix metalloproteinase-3 (MMP-3), and nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3), was assessed in joint tissue using quantitative reverse transcription PCR (RT-PCR). Results: Combined treatment with GLENVs and celastrol markedly decreased serum levels of the proinflammatory cytokines TNF-α, IL-1β, and IL-6 and increased levels of the anti-inflammatory cytokines IL-10 and TGF-β. Furthermore, mRNA expression of JAK1, STAT3, COX-2, MMP-3, and NLRP3 was significantly reduced, suggesting transcriptional suppression of inflammatory pathways. Conclusions: These findings suggest that combining GLENVs with celastrol could provide a novel, natural nanotherapeutic platform to suppress inflammation and regulate immune responses in RA.